FR14C0049I1 - - Google Patents

Info

Publication number
FR14C0049I1
FR14C0049I1 FR14C0049C FR14C0049I1 FR 14C0049 I1 FR14C0049 I1 FR 14C0049I1 FR 14C0049 C FR14C0049 C FR 14C0049C FR 14C0049 I1 FR14C0049 I1 FR 14C0049I1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32185709&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR14C0049(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of FR14C0049I1 publication Critical patent/FR14C0049I1/fr
Application granted granted Critical
Publication of FR14C0049I2 publication Critical patent/FR14C0049I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR14C0049C 2002-11-15 2014-06-23 Nouveaux medicaments destines au traitement de la bronchopneumopathie chronique obstructive Active FR14C0049I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10253282A DE10253282A1 (de) 2002-11-15 2002-11-15 Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung
PCT/EP2003/012565 WO2004045618A2 (de) 2002-11-15 2003-11-11 Neue arzneimittel zur behandlung von chronisch obstruktiver lungenerkrankung

Publications (2)

Publication Number Publication Date
FR14C0049I1 true FR14C0049I1 (enrdf_load_stackoverflow) 2014-08-08
FR14C0049I2 FR14C0049I2 (fr) 2015-07-24

Family

ID=32185709

Family Applications (1)

Application Number Title Priority Date Filing Date
FR14C0049C Active FR14C0049I2 (fr) 2002-11-15 2014-06-23 Nouveaux medicaments destines au traitement de la bronchopneumopathie chronique obstructive

Country Status (38)

Country Link
EP (2) EP2025338A1 (enrdf_load_stackoverflow)
JP (1) JP4317138B2 (enrdf_load_stackoverflow)
KR (1) KR101092247B1 (enrdf_load_stackoverflow)
CN (3) CN101735166A (enrdf_load_stackoverflow)
AR (2) AR041969A1 (enrdf_load_stackoverflow)
AT (1) ATE430569T1 (enrdf_load_stackoverflow)
AU (1) AU2003285326B2 (enrdf_load_stackoverflow)
BE (1) BE2014C016I2 (enrdf_load_stackoverflow)
BR (1) BRPI0316264B8 (enrdf_load_stackoverflow)
CA (1) CA2506082C (enrdf_load_stackoverflow)
CO (1) CO5570670A2 (enrdf_load_stackoverflow)
CY (2) CY1110500T1 (enrdf_load_stackoverflow)
DE (2) DE10253282A1 (enrdf_load_stackoverflow)
DK (1) DK1562603T3 (enrdf_load_stackoverflow)
EA (1) EA008665B1 (enrdf_load_stackoverflow)
EC (1) ECSP055774A (enrdf_load_stackoverflow)
ES (1) ES2326878T7 (enrdf_load_stackoverflow)
FR (1) FR14C0049I2 (enrdf_load_stackoverflow)
HR (1) HRP20050432B1 (enrdf_load_stackoverflow)
HU (1) HUS1400011I1 (enrdf_load_stackoverflow)
IL (1) IL167900A (enrdf_load_stackoverflow)
LT (1) LTC1562603I2 (enrdf_load_stackoverflow)
LU (1) LU92433I2 (enrdf_load_stackoverflow)
ME (1) ME00354B (enrdf_load_stackoverflow)
MX (1) MXPA05005081A (enrdf_load_stackoverflow)
MY (1) MY136034A (enrdf_load_stackoverflow)
NL (1) NL300650I2 (enrdf_load_stackoverflow)
NO (2) NO334314B1 (enrdf_load_stackoverflow)
NZ (1) NZ540661A (enrdf_load_stackoverflow)
PE (1) PE20040694A1 (enrdf_load_stackoverflow)
PL (1) PL212238B1 (enrdf_load_stackoverflow)
PT (1) PT1562603E (enrdf_load_stackoverflow)
RS (1) RS51607B (enrdf_load_stackoverflow)
SI (1) SI1562603T1 (enrdf_load_stackoverflow)
TW (1) TWI343812B (enrdf_load_stackoverflow)
UA (1) UA81276C2 (enrdf_load_stackoverflow)
WO (1) WO2004045618A2 (enrdf_load_stackoverflow)
ZA (1) ZA200502246B (enrdf_load_stackoverflow)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7056916B2 (en) 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
DE102004019539A1 (de) * 2004-04-22 2005-11-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittel zur Behandlung von Atemwegserkrankungen
SG152237A1 (en) * 2004-04-22 2009-05-29 Boehringer Ingelheim Int Pharmaceutical combinations containing benzoxazine for treating respiratory diseases
JP2007537187A (ja) * 2004-05-13 2007-12-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 呼吸器疾患の治療においてβアゴニストとして使用するためのヒドロキシ置換ベンゾ縮合ヘテロ環化合物
DE102004024451A1 (de) * 2004-05-14 2005-12-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverformulierungen für die Inhalation, die Enantiomerenreine Betaagonisten enthalten
US7745621B2 (en) 2004-05-14 2010-06-29 Boehringer Ingelheim International Gmbh Long acting bronchodilators for the treatment of respiratory diseases
DE102004024454A1 (de) * 2004-05-14 2005-12-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Enantiomerenreine Betaagonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE102004024453A1 (de) * 2004-05-14 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Bronchodilatoren zur Behandlung von Atemwegserkrankungen
DE102004024452A1 (de) * 2004-05-14 2005-12-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosolformulierung für die Inhalation von Betaagonisten
US20050256115A1 (en) * 2004-05-14 2005-11-17 Boehringer Ingelheim International Gmbh Aerosol formulation for the inhalation of beta-agonists
US7220742B2 (en) 2004-05-14 2007-05-22 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
DE102004045648A1 (de) * 2004-09-21 2006-03-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Betamimetika zur Behandlung von Atemwegserkrankungen
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
DE102005007654A1 (de) * 2005-02-19 2006-08-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Betamimetika zur Behandlung von Atemwegserkrankungen
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
DE102005030733A1 (de) * 2005-07-01 2007-01-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen enthaltend langwirksame Beta-2-Agonisten und wenigstens einen weiteren Wirkstoff
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
EP2281813A1 (en) 2005-08-08 2011-02-09 Pulmagen Therapeutics (Synergy) Limited Bicyclo[2.2.1]hept-7-ylamine derivatives and their uses
ES2530991T3 (es) 2005-08-15 2015-03-09 Boehringer Ingelheim Int Procedimiento para la obtención de betamiméticos
US20070088030A1 (en) 2005-10-10 2007-04-19 Barbara Niklaus-Humke Aerosol formulations for the inhalation of beta-agonists
TWI396541B (zh) * 2005-10-10 2013-05-21 Boehringer Ingelheim Int 用於治療呼吸疾病之新穎藥物組合
US7910708B2 (en) 2005-10-21 2011-03-22 Novartis Ag Anti-IL13 human antibodies
EP1948186A1 (en) * 2005-11-09 2008-07-30 Boehringer Ingelheim International Gmbh Aerosolformulation for inhalation
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
EP1986644A1 (de) * 2006-02-16 2008-11-05 Boehringer Ingelheim International GmbH Arzneimittelkombinationen zur behandlung von atemwegserkrankungen
PE20080142A1 (es) 2006-03-15 2008-04-14 Boehringer Ingelheim Int Beta-agonistas enantiomericamente puros y sus procedimientos de preparacion
PE20080361A1 (es) 2006-04-21 2008-06-03 Novartis Ag Compuestos derivados de purina como activadores del receptor de adenosina a2a
JP2010500319A (ja) * 2006-08-07 2010-01-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 鏡像体上純粋な新規ベータアゴニスト、それらの製造方法及び医薬としてのそれらの使用
UY30543A1 (es) * 2006-08-18 2008-03-31 Boehringer Ingelheim Int Formulacion de aerosol para la inhalacion de beta- agonistas
UY30542A1 (es) * 2006-08-18 2008-03-31 Boehringer Ingelheim Int Formulacion de aerosol para la inhalacion de agonistas beta
US20090286779A1 (en) 2006-09-29 2009-11-19 Novartis Ag Pyrazolopyrimidines as lipid kinase inhibitors
US20100041662A1 (en) 2006-10-30 2010-02-18 Sandrine Ferrand Heterocyclic compounds as antiinflammatory agents
DK2104535T3 (da) 2007-01-10 2011-04-04 Irm Llc Forbindelser og sammensætninger som kanalaktiverende proteaseinhibitorer
DK2125759T3 (da) * 2007-01-25 2011-09-19 Boehringer Ingelheim Int Fremgangsmåde til fremstilling af betamimetika
EP2155721B1 (en) 2007-05-07 2011-02-23 Novartis AG Organic compounds
CA2707857C (en) 2007-12-10 2016-09-13 Novartis Ag Spirocyclic amiloride analogues
JP5584138B2 (ja) 2008-01-11 2014-09-03 ノバルティス アーゲー キナーゼ阻害剤としてのピリミジン類
EA201001848A1 (ru) 2008-06-10 2011-08-30 Новартис Аг Производные пиразина в качестве блокаторов эпителиальных натриевых каналов
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
WO2010076553A1 (en) 2008-12-30 2010-07-08 Dr. Reddy's Laboratories Ltd Sulfonamide compounds for the treatment of respiratory disorders
SI2391366T1 (sl) 2009-01-29 2013-01-31 Novartis Ag Substituirani benzimidazoli za zdravljenje astrocitomov
WO2010150014A1 (en) 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
BR112012003262A8 (pt) 2009-08-12 2016-05-17 Novartis Ag compostos de hidrazona heterocíclica e seus usos para tratar câncer e inflamação
PT2467141T (pt) 2009-08-17 2019-02-06 Intellikine Llc Compostos heterocíclicos e suas utilizações
EP2490687A1 (en) 2009-10-22 2012-08-29 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
WO2011098746A1 (en) 2010-02-09 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
GB201002243D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
GB201002224D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
JP6084926B2 (ja) * 2010-09-21 2017-02-22 インテクリン・セラピユーテイクス・インコーポレイテツド 抗糖尿病固体医薬組成物
WO2012107500A1 (en) 2011-02-10 2012-08-16 Novartis Ag [1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
SG192795A1 (en) 2011-02-25 2013-09-30 Irm Llc Compounds and compositions as trk inhibitors
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
UY34329A (es) 2011-09-15 2013-04-30 Novartis Ag Compuestos de triazolopiridina
US9056867B2 (en) 2011-09-16 2015-06-16 Novartis Ag N-substituted heterocyclyl carboxamides
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
US9034879B2 (en) 2011-09-16 2015-05-19 Novartis Ag Heterocyclic compounds for the treatment of CF
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
US20130209543A1 (en) 2011-11-23 2013-08-15 Intellikine Llc Enhanced treatment regimens using mtor inhibitors
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
AU2013243097A1 (en) 2012-04-03 2014-10-09 Novartis Ag Combination products with tyrosine kinase inhibitors and their use
WO2014056840A1 (en) 2012-10-09 2014-04-17 Boehringer Ingelheim International Gmbh Beta-2-adrenoceptor agonist for the treatment of cough
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
EP2968340A4 (en) 2013-03-15 2016-08-10 Intellikine Llc COMBINING KINASE INHIBITORS AND USES THEREOF
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
CA2945069A1 (en) 2014-04-24 2015-10-29 Novartis Ag Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors
JP6433509B2 (ja) 2014-04-24 2018-12-05 ノバルティス アーゲー ホスファチジルイノシトール３−キナーゼ阻害薬としてのアミノピラジン誘導体
JP6404944B2 (ja) 2014-04-24 2018-10-17 ノバルティス アーゲー ホスファチジルイノシトール３−キナーゼ阻害薬としてのピラジン誘導体
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
MX373272B (es) 2014-07-31 2020-04-16 Novartis Ag Terapia de combinacion.
CN110062625A (zh) 2016-12-12 2019-07-26 勃林格殷格翰国际有限公司 尼达尼布通过与奥达特罗共给予用于治疗间质性肺病的方法
JP7116060B2 (ja) 2016-12-20 2022-08-09 インケ、ソシエダ、アノニマ Ｒ－６－ヒドロキシ－８－［１－ヒドロキシ－２－［２－（４－メトキシフェニル）－１，１－ジメチルエチルアミノエチル］－２ｈ－１，４－ベンゾオキサジン－３（４ｈ）－オン塩酸塩の改良された製造法
CN109096218B (zh) * 2018-08-06 2020-10-27 上海方予健康医药科技有限公司 盐酸奥达特罗晶型a及其制备方法
CN108997248B (zh) * 2018-08-06 2023-08-01 上海方予健康医药科技有限公司 盐酸奥达特罗晶型b及其制备方法
JP2022537667A (ja) 2019-06-10 2022-08-29 ノバルティス アーゲー Ｃｆ、ｃｏｐｄ、及び気管支拡張症の治療のためのピリジン及びピラジン誘導体
MX2022002374A (es) 2019-08-28 2022-03-29 Novartis Ag Derivados de 1,3-fenil heteroarilo sustituidos y su uso en el tratamiento de enfermedades.
US11304897B2 (en) 2020-06-09 2022-04-19 Anovent Pharmaceutical (U.S.), Llc Pharmaceutical formulation containing umeclidinium bromide and vilanterol trifenatate
US11331322B1 (en) 2021-09-15 2022-05-17 Santen Pharmaceutical Co., Ltd. Medicament for preventing and/or treating dry eye

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3134590A1 (de) * 1981-09-01 1983-03-10 Boehringer Ingelheim KG, 6507 Ingelheim Neue benzo-heterocyclen
US4460581A (en) 1982-10-12 1984-07-17 Boehringer Ingelheim Kg (1-Hydroxy-2-amino-alkyl)-substituted benzoxazinones and benzoxazolinones
DE3743265A1 (de) * 1987-12-19 1989-06-29 Boehringer Ingelheim Kg Neue ammoniumverbindungen, ihre herstellung und verwendung
MXPA02010179A (es) * 2000-04-27 2003-04-25 Boehringer Ingelheim Pharma Nuevos betamimeticos de larga accion, procedimiento para su preparacion y su empleo como medicamentos.

Also Published As

Publication number Publication date
AU2003285326B2 (en) 2009-06-04
HRP20050432B1 (en) 2012-01-31
HRP20050432A2 (en) 2006-06-30
CN101817800A (zh) 2010-09-01
SI1562603T1 (sl) 2009-10-31
NO2014005I1 (no) 2014-03-10
JP4317138B2 (ja) 2009-08-19
CA2506082C (en) 2011-06-21
JP2006508140A (ja) 2006-03-09
ME00354B (me) 2011-10-10
BE2014C016I2 (enrdf_load_stackoverflow) 2023-03-07
CN1713914A (zh) 2005-12-28
MY136034A (en) 2008-07-31
EA008665B1 (ru) 2007-06-29
ECSP055774A (es) 2005-11-22
CN101735166A (zh) 2010-06-16
RS20050361A (sr) 2007-04-10
EP1562603B1 (de) 2009-05-06
MXPA05005081A (es) 2005-07-01
UA81276C2 (en) 2007-12-25
HUS1400011I1 (hu) 2022-02-28
LTC1562603I2 (lt) 2016-12-12
CY2014032I1 (el) 2015-12-09
NO334314B1 (no) 2014-02-03
NZ540661A (en) 2007-12-21
WO2004045618A3 (de) 2004-09-30
AR087241A2 (es) 2014-03-12
AR041969A1 (es) 2005-06-01
ES2326878T3 (es) 2009-10-21
BRPI0316264B1 (pt) 2019-04-09
CO5570670A2 (es) 2005-10-31
KR101092247B1 (ko) 2011-12-12
ES2326878T7 (es) 2014-03-11
DE50311502D1 (de) 2009-06-18
PL375270A1 (en) 2005-11-28
CY2014032I2 (el) 2015-12-09
EP1562603B3 (de) 2014-01-08
PT1562603E (pt) 2009-06-18
AU2003285326A1 (en) 2004-06-15
NL300650I2 (nl) 2017-11-02
DK1562603T3 (da) 2009-09-07
EP1562603A2 (de) 2005-08-17
NO20052883L (no) 2005-06-14
PE20040694A1 (es) 2004-11-23
TWI343812B (en) 2011-06-21
EA200500715A1 (ru) 2005-12-29
TW200423943A (en) 2004-11-16
WO2004045618A2 (de) 2004-06-03
RS51607B (sr) 2011-08-31
CA2506082A1 (en) 2004-06-03
ATE430569T1 (de) 2009-05-15
DE10253282A1 (de) 2004-05-27
EP2025338A1 (de) 2009-02-18
BR0316264A (pt) 2005-10-11
LU92433I2 (fr) 2014-06-24
BRPI0316264B8 (pt) 2021-05-25
ZA200502246B (en) 2006-01-25
PL212238B1 (pl) 2012-08-31
CY1110500T1 (el) 2015-04-29
FR14C0049I2 (fr) 2015-07-24
IL167900A (en) 2013-06-27
MEP53608A (en) 2011-05-10
KR20050075013A (ko) 2005-07-19

Similar Documents

Publication Publication Date Title
BE2019C547I2 (enrdf_load_stackoverflow)
BE2019C510I2 (enrdf_load_stackoverflow)
BE2018C021I2 (enrdf_load_stackoverflow)
BE2017C049I2 (enrdf_load_stackoverflow)
BE2017C005I2 (enrdf_load_stackoverflow)
BE2016C069I2 (enrdf_load_stackoverflow)
BE2018C018I2 (enrdf_load_stackoverflow)
DE60335752D1 (enrdf_load_stackoverflow)
FR14C0049I1 (enrdf_load_stackoverflow)
BE2014C015I2 (enrdf_load_stackoverflow)
BE2013C039I2 (enrdf_load_stackoverflow)
BE2013C025I2 (enrdf_load_stackoverflow)
BE2011C038I2 (enrdf_load_stackoverflow)
JP2003190159A5 (enrdf_load_stackoverflow)
JP2003201610A5 (enrdf_load_stackoverflow)
BE2015C069I2 (enrdf_load_stackoverflow)
JP2003220846A5 (enrdf_load_stackoverflow)
JP2003238174A5 (enrdf_load_stackoverflow)
JP2003191601A5 (enrdf_load_stackoverflow)
BE2013C046I2 (enrdf_load_stackoverflow)
JP2003096003A5 (enrdf_load_stackoverflow)
JP2003176408A5 (enrdf_load_stackoverflow)
JP2003202034A5 (enrdf_load_stackoverflow)
JP2003175899A5 (enrdf_load_stackoverflow)
JP2003154687A5 (enrdf_load_stackoverflow)